《Cell,8月14日,Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-08-18
  • Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

    Takuya Sekine 13

    André Perez-Potti 13

    Olga Rivera-Ballesteros 13

    Hans-Gustaf Ljunggren 13

    Soo Aleman 13

    Marcus Buggert 13, 15

    Show all authors

    Show footnotes

    Open AccessPublished:August 14, 2020DOI:https://doi.org/10.1016/j.cell.2020.08.017

    Summary

    SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. We here systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19. Acute phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convalescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits robust, broad and highly functional memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19.

  • 原文来源:https://www.cell.com/cell/fulltext/S0092-8674(20)31008-4
相关报告
  • 《CELL,5月14日,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-05-16
    • in humans with COVID-19 disease and unexposed individuals Alba Grifoni Daniela Weiskopf Sydney I. Ramirez Published:May 14, 2020DOI:https://doi.org/10.1016/j.cell.2020.05.015 Summary Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The M, spike and N proteins each accounted for 11-27% of the total CD4+ response, with additional responses commonly targeting nsp3, nsp4, ORF3a and ORF8, among others. For CD8+ T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we detected SARS-CoV-2−reactive CD4+ T cells in ∼40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2.
  • 《Nature,12月24日,Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-01
    • Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19 Hong-Yi Zheng, Min Xu, Cui-Xian Yang, Ren-Rong Tian, Mi Zhang, Jian-Jian Li, Xi-Cheng Wang, Zhao-Li Ding, Gui-Mei Li, Xiao-Lu Li, Yu-Qi He, Xing-Qi Dong, Yong-Gang Yao & Yong-Tang Zheng Signal Transduction and Targeted Therapy volume 5, Article number: 294 (2020) Abstract Understanding the processes of immune regulation in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for improving treatment. Here, we performed longitudinal whole-transcriptome RNA sequencing on peripheral blood mononuclear cell (PBMC) samples from 18 patients with coronavirus disease 2019 (COVID-19) during their treatment, convalescence, and rehabilitation. After analyzing the regulatory networks of differentially expressed messenger RNAs (mRNAs), microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) between the different clinical stages, we found that humoral immunity and type I interferon response were significantly downregulated, while robust T-cell activation and differentiation at the whole transcriptome level constituted the main events that occurred during recovery from COVID-19. The formation of this T cell immune response might be driven by the activation of activating protein-1 (AP-1) related signaling pathway and was weakly affected by other clinical features. These findings uncovered the dynamic pattern of immune responses and indicated the key role of T cell immunity in the creation of immune protection against this disease.